Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52

Benzinga Newsdesk www.benzinga.com Positive 85.8%

Neg 0% Neu 0% Pos 85.8%

Baird analyst Joel Beatty maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $28 to $52.